NewsFeed Voices Science Insight Innovation
December, 2025
December 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  
Dr. Rawnak Sharif: Managing Proximal Lower-Limb DVT or PE is No Longer Just About Choosing an Anticoagulant
Dr. Rawnak Sharif/LinkedIn
Dec 5, 2025, 03:43

Dr. Rawnak Sharif: Managing Proximal Lower-Limb DVT or PE is No Longer Just About Choosing an Anticoagulant

Dr. Rawnak Sharif, Resident Medical Officer at Apollo Imperial Hospital, posted on LinkedIn:

“Modern, Evidence-Based Management of DVT: A Practical 2025 Guide

Here’s the thing. Managing proximal lower-limb DVT or PE is no longer just about choosing an anticoagulant. The real work is deciding how long to treat and who needs lifelong protection. The latest ASH, ESC, NICE, CHEST, and ISTH updates all point in the same direction: simplify the pathway and individualize duration.

Dr. Rawnak Sharif: Managing Proximal Lower-Limb DVT or PE is No Longer Just About Choosing an Anticoagulant

1. First Line Therapy (First 3 Months)
All confirmed proximal DVT or PE requires at least three months of therapeutic anticoagulation.
Preferred options remain DOACs:
Apixaban 10 mg BID for 7 days, then 5 mg BID
Rivaroxaban 15 mg BID for 21 days, then 20 mg daily
Dabigatran 150 mg BID (after 5–10 days of heparin)
Edoxaban 60 mg daily (after heparin lead-in)
Warfarin only if DOACs are unsuitable.
Evidence across guidelines consistently supports DOACs for superior safety and convenience.

2. After 3 Months: The Key Decision
This is where outcomes diverge.

Provoked DVT (clear temporary risk factor)
Surgery, trauma, immobility, long-haul travel, estrogen therapy.
Stop at 3 months. No D-dimer. Recurrence is very low.

Unprovoked DVT or PE
Recurrence risk is high. Extended therapy is recommended unless bleeding risk is prohibitive.
You can stay on full-dose DOAC or switch to reduced-dose long-term prophylaxis.
A D-dimer 4–6 weeks after stopping helps refine risk:
Normal → observation reasonable.
Elevated → restart anticoagulation.

Persistent Risk Factors
Cancer, major thrombophilia, chronic inflammatory disease, recurrent events.
These patients need indefinite therapy. D-dimer does not guide decisions here.

3. Extended-Phase Anticoagulation (After 3–6 Months)
Reduced-dose DOACs have become the standard for ongoing protection:
Apixaban 2.5 mg BID
Rivaroxaban 10 mg daily
These doses maintain 80–90% recurrence reduction with minimal bleeding risk.

4. D-Dimer: When to Use It and When to Avoid It
Use only in unprovoked cases and only after stopping treatment for 4–6 weeks.
Avoid during acute illness, pregnancy, postpartum, cancer, or while on anticoagulation—results will mislead you.

What this really means is that modern DVT care is simpler than it looks. Assess the trigger, weigh the long-term risk, and use DOACs thoughtfully. Once you internalize those steps, the rest falls into place.

References (Short)
ASH VTE Guidelines 2018/2020
ESC Pulmonary Embolism Guidelines 2019
NICE VTE NG158 (2023 updates)
CHEST VTE Antithrombotic Therapy 2021/2024
ISTH Scientific and practice guidance (2019–2024)”

Stay informed with Hemostasis Today.

2025 Guide Apixaban ASH CHEST dabigatran Dr. Rawnak Sharif DVT edoxaban ESC Health Hematology Hemostasis Hemostasis Today ISTH Medicine NICE PE Rivaroxaban Warfarin
NewsFeed